NCT01486914 is a Phase 1 clinical trial of insulin aspart in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT01486914?

NCT01486914 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT01486914?

Interventions in NCT01486914: insulin aspart.

What condition does NCT01486914 study?

NCT01486914 studies Diabetes, Healthy.

Is NCT01486914 still recruiting?

NCT01486914 is currently completed. Last updated 1 March 2017.

Last reviewed 2017-03-01 · How we verify

NCT01486914

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process

Completed Phase 1 Last updated 1 March 2017

What this trial tests

Phase 1 trial testing insulin aspart in Diabetes in 28 participants. Completed in 24 February 2003.

Timeline

19 January 2003

Primary endpoint
24 February 2003

24 February 2003

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	28
Start date	19 January 2003
Primary completion	24 February 2003
Estimated completion	24 February 2003
Sites	1 location across United Kingdom

Drugs / interventions tested

insulin aspart (INSULIN ASPART) — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Healthy — all drugs for Healthy →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 50, male only, with Diabetes or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Europe. The aim of this trial is to compare insulin aspart produced by current process and the NN2000 process.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of insulin aspart

Trials testing the same drug.

NCT05946785 — Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes · EARLY_PHASE1 · recruiting
NCT05013229 — A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semagluti · Phase 3 · completed
NCT04848480 — A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both · Phase 3 · completed
NCT02825251 — Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® i · Phase 3 · completed
NCT02500706 — Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in · Phase 3 · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01486914 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 1 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01486914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing